| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
|---|---|---|---|---|---|---|
| 2020 | Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7) | Harbeck N.; Franke F.; Villanueva-Vazquez R.; YEN-SHEN LU ; Tripathy D.; Chow L.; Babu G.K.; Im Y.-H.; Chandiwana D.; Gaur A.; Lanoue B.; Rodriguez-Lorenc K.; Bardia A. | Therapeutic Advances in Medical Oncology | 32 | 29 | |
| 2021 | Matching-adjusted indirect comparison of ribociclib plus fulvestrant versus palbociclib plus letrozole as first-line treatment of hr+/her2? advanced breast cancer | Fasching P.A.; Delea T.E.; YEN-SHEN LU ; De Boer R.; Hurvitz S.A.; Moynahan A.; Chandiwana D.; Lanoue B.; Hu H.; Thuerigen A.; O��shaughnessy J. | Cancer Management and Research | 0 | 0 |
